Issue Date: August 10, 2009
Cleveland Clinic Invests In Small Firm
Cleveland Clinic, a leading academic medical center, has taken an equity stake in FTA Therapeutics, a Pennsylvania-based developer of antimicrobials, in return for conducting clinical studies with FTA. The studies will be part of a project between FTA and biotech firm Pure Bioscience focused on a silver dihydrogen citrate (SDC) antimicrobial. FTA is completing preclinical work on SDC formulations to prepare for trials on wound care and acne later this year.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society